Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
SUBLOCADE
product2 mentionslast seen Nov 2, 2026
Marketed medicine in the combined company's portfolio for opioid use disorder.
Relationships 2
Relationship
Supernus Pharmaceuticals, Inc.commercializesSUBLOCADE
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 2, 2026SUPERNUS PHARMACEUTICALS, INC. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 2.01: Completion of Acquisition or Disposition of Assets; Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Item 3.03: Material Modifications to Rights of Security Holders; Item 5.01: Changes in Control of Registrant; Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
An 11-product portfolio spans opioid use disorder, psychiatry, and neurology, and includes five core growth drivers – SUBLOCADE®
- filingSEC EDGARNov 2, 2026Indivior Pharmaceuticals, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 2.01: Completion of Acquisition or Disposition of Assets; Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
An 11-product portfolio spans opioid use disorder, psychiatry, and neurology, and includes five core growth drivers – SUBLOCADE®